We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced ...

On Tuesday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.24 or -7.59% from the prior close of $3.16. The stock opened at $3.17 and ...

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

Sana Biotechnology (NASDAQ:SANA – Free Report) had its price target boosted by HC Wainwright from $8.00 to $11.00 in a report ...

Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $3.16 which represents a decrease of $-0.09 or -2.77% from the prior close of $3.25. The stock opened at $3.15 and touched a low of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Sana is a gene and cell therapy clinical-stage biotech firm and a penny stock that has fallen by 48.5% in the year leading to January 17, 2025. What may set this company apart from a host of similar ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated look at SANA stock following its news.

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target remains the same with $15.00. Discover ...